164 related articles for article (PubMed ID: 25085780)
1. Heterogeneity research in muscle-invasive bladder cancer based on differential protein expression analysis.
Liu PF; Cao YW; Jiang HP; Wang YH; Yang XC; Wang XS; Niu HT
Med Oncol; 2014 Sep; 31(9):21. PubMed ID: 25085780
[TBL] [Abstract][Full Text] [Related]
2. Far from resolved: stromal cell-based iTRAQ research of muscle-invasive bladder cancer regarding heterogeneity.
Liu PF; Wang YH; Cao YW; Jiang HP; Yang XC; Wang XS; Niu HT
Oncol Rep; 2014 Oct; 32(4):1489-96. PubMed ID: 25050759
[TBL] [Abstract][Full Text] [Related]
3. Cancer stroma proteome expression profile of superficial bladder transitional cell carcinoma and biomarker discovery.
Niu HT; Yang CM; Jiang G; Xu T; Cao YW; Zhao J; Wang XS
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1273-82. PubMed ID: 21706132
[TBL] [Abstract][Full Text] [Related]
4. Extracellular matrix-related genes play an important role in the progression of NMIBC to MIBC: a bioinformatics analysis study.
Zhang H; Shan G; Song J; Tian Y; An LY; Ban Y; Luo GH
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32391563
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer.
Sahu D; Lotan Y; Wittmann B; Neri B; Hansel DE
Cancer Med; 2017 Sep; 6(9):2106-2120. PubMed ID: 28766915
[TBL] [Abstract][Full Text] [Related]
6. Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer.
Chen CL; Chung T; Wu CC; Ng KF; Yu JS; Tsai CH; Chang YS; Liang Y; Tsui KH; Chen YT
Mol Cell Proteomics; 2015 Sep; 14(9):2466-78. PubMed ID: 26081836
[TBL] [Abstract][Full Text] [Related]
7. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
8. Proteome-based classification of Nonmuscle Invasive Bladder Cancer.
Stroggilos R; Mokou M; Latosinska A; Makridakis M; Lygirou V; Mavrogeorgis E; Drekolias D; Frantzi M; Mullen W; Fragkoulis C; Stasinopoulos K; Papadopoulos G; Stathouros G; Lazaris AC; Makrythanasis P; Ntoumas K; Mischak H; Zoidakis J; Vlahou A
Int J Cancer; 2020 Jan; 146(1):281-294. PubMed ID: 31286493
[TBL] [Abstract][Full Text] [Related]
9. Differences in shotgun protein expression profile between superficial bladder transitional cell carcinoma and normal urothelium.
Niu HT; Zhang YB; Jiang HP; Cheng B; Sun G; Wang Y; E YJ; Pang de Q; Chang JW
Urol Oncol; 2009; 27(4):400-6. PubMed ID: 18818109
[TBL] [Abstract][Full Text] [Related]
10. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
11. Parallel proteomic analysis in muscle-invasive bladder transitional cell carcinoma and cancer-related stroma.
Niu HT; Qi XJ; Liu YQ; Cao YW; Dong Q; Wang XS
Genet Mol Res; 2013 Feb; 12(4):4251-63. PubMed ID: 23479173
[TBL] [Abstract][Full Text] [Related]
12. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.
DeGraff DJ; Clark PE; Cates JM; Yamashita H; Robinson VL; Yu X; Smolkin ME; Chang SS; Cookson MS; Herrick MK; Shariat SF; Steinberg GD; Frierson HF; Wu XR; Theodorescu D; Matusik RJ
PLoS One; 2012; 7(5):e36669. PubMed ID: 22590586
[TBL] [Abstract][Full Text] [Related]
13. Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis.
Barboro P; Rubagotti A; Orecchia P; Spina B; Truini M; Repaci E; Carmignani G; Romagnoli A; Introini C; Boccardo F; Carnemolla B; Balbi C
Cell Oncol; 2008; 30(1):13-26. PubMed ID: 18219107
[TBL] [Abstract][Full Text] [Related]
14. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
[TBL] [Abstract][Full Text] [Related]
15. Application of Label-Free Proteomics for Quantitative Analysis of Urothelial Carcinoma and Cystitis Tissue.
Witzke KE; Großerueschkamp F; Gerwert K; Sitek B
Methods Mol Biol; 2021; 2228():283-292. PubMed ID: 33950498
[TBL] [Abstract][Full Text] [Related]
16. [New exploration of treatment target for proliferative diabetic retinopathy based on iTRAQ LC-MS/MS Proteomics].
Wen DJ; Ren XJ; Dong LJ; He Y; Li XR
Zhonghua Yan Ke Za Zhi; 2019 Oct; 55(10):769-776. PubMed ID: 31607066
[No Abstract] [Full Text] [Related]
17. Increased expression of L-selectin (CD62L) in high-grade urothelial carcinoma: A potential marker for metastatic disease.
Choudhary D; Hegde P; Voznesensky O; Choudhary S; Kopsiaftis S; Claffey KP; Pilbeam CC; Taylor JA
Urol Oncol; 2015 Sep; 33(9):387.e17-27. PubMed ID: 25618296
[TBL] [Abstract][Full Text] [Related]
18. Systems Drug Design for Muscle Invasive Bladder Cancer and Advanced Bladder Cancer by Genome-Wide Microarray Data and Deep Learning Method with Drug Design Specifications.
Su PW; Chen BS
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430344
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic significance of pyruvate dehydrogenase kinase 1 in bladder urothelial carcinoma.
Zhu J; Zheng G; Xu H; Jin X; Tang T; Wang X
Virchows Arch; 2020 Nov; 477(5):637-649. PubMed ID: 32388719
[TBL] [Abstract][Full Text] [Related]
20. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
